Skip to main content

Advertisement

SpringerLink
Log in

An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate

  • Spotlight Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.

    Article  CAS  Google Scholar 

  2. Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR–ABL. Cell 2003; 112: 831–843.

    Article  CAS  Google Scholar 

  3. Hantschel O, Superti-Furga G . Regulation of the c-Abl and bcr–abl tyrosine kinases. Nat Rev Mol Cell Biol 2004; 5: 33–45.

    Article  CAS  Google Scholar 

  4. Goldman JM . Chronic myeloid leukemia-still a few questions. Exp Hematol 2004; 32: 2–10.

    Article  Google Scholar 

  5. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.

    Article  CAS  Google Scholar 

  6. Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of inhibition of the ABL kinase by STI571. J Biol Chem 2002; 27: 32214–32219.

    Article  Google Scholar 

  7. Warmuth M, Simon N, Mitina O, Mathes R, Fabbro D, Manley PW et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. Blood 2003; 101: 664–672.

    Article  CAS  Google Scholar 

  8. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by ‘Ligue contre le cancer’ and ‘Association pour la Recherche contre le Cancer’.

Author information

Authors and Affiliations

  1. Laboratoire hématopoïèse leucémique et cible thérapeutique INSERM E0217, Université Victor Segalen Bordeaux II, France

    T Leguay, V Desplat, V Lagarde, G Marit, J Reiffers & F-X Mahon

  2. Service des Maladies du Sang, Hôpital du Haut-Lévèque, Pessac, France

    T Leguay, G Marit, J Reiffers & F-X Mahon

Authors
  1. T Leguay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Desplat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V Lagarde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Marit
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Reiffers
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F-X Mahon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F-X Mahon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leguay, T., Desplat, V., Lagarde, V. et al. An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate. Leukemia 19, 1671–1673 (2005). https://doi.org/10.1038/sj.leu.2403831

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403831

  • Springer Nature Limited

This article is cited by

Search

Navigation